Oral bioavailability of trovafloxacin with and without food in healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 87-92

  Teng, Renli ^a   Dogolo, Lisa C ^a   Willavize, Susan A ^a   Friedman, Hylar L ^a   Vincent, John ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG URINE LEVEL; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030805572     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.87     Document Type: Article

References (24)

1. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
2. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-370.
3. Girard, A. E., Faiella, J. A., Cimochowski, C. R. & Brighty, K. E. (1993). In vivo oral activity of CP-99,219 in models of acute and localized infection. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1510, p. 395. American Society for Microbiology, Washington, DC.
4. Neu, H. C. & Chin, N.-X. (1994). In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
5. 14C]CP-99,219 into gastric tissue of Long-Evans rats and Swiss-Webster mice following intravenous administration. In Abstracts of the Seventh European Conference of Clinical Microbiology and Infectious Diseases, Vienna, 1995. Abstract 747, p. 144. European Society of Clinical Microbiology and Infectious Diseases.
6. Teng, R., Girard, D., Gootz, T. D., Foulds, G. & Liston, T. E. (1996). Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone in rats, dogs, and monkeys. Antimicrobial Agents and Chemotherapy 40, 561-566.
7. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995). Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.
8. Teng, R., Liston, T. E. & Harris, S. C. (1996). Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 37, 955-63.
9. Brighty, K. E., Gootz, T. D., Girard, A., Shanker, R., Castaldi, M. J., Girard, D. et al. (1995). Prodrugs of CP-99,219 for intravenous administration: synthesis and evaluation resulting in identification of CP-116,517. In Abstracts of the Seventh European Conference of Clinical Microbiology and Infectious Diseases, Vienna, 1995. Abstract 730, p. 141. European Society of Clinical Microbiology and Infectious Diseases.
10. Teng, R., Baris, B. A., Willavize, S. A., Polzer, R. J. & Vincent, J. (1995). Pharmacokinetics and safety in healthy male volunteers of CP-116,517, the prodrug of trovafloxacin (CP-99,219), after administration of single intravenous doses. Canadian Journal of Infectious Disease 6, Suppl. C, 445C.
11. Teng, R., Vincent, J., Baris, B. & Willavize, S. (1995). Pharmacokinetics of single and multiple intravenous doses of CP-116,517, the prodrug of trovafloxacin (CP-99,219) in healthy male volunteers. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1993. Abstract F240, p. 155. American Society for Microbiology, Washington, DC.
12. Ledergerber, B., Bettex, J.-D., Joos, B., Flepp, M. & Lüthy, R. (1985). Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrobial Agents and Chemotherapy 27, 350-2.
13. Somogyi, A. A., Bochner, F., Keal, J. A., Rolan, P. E. & Smith, M. (1987). Effect of food on enoxacin absorption. Antimicrobial Agents and Chemotherapy 31, 638-9.
14. Höffken, G., Lode, H., Wiley, R., Glatzel, T. D., Sievers, D., Olschewski, T. et al. (1988). Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Reviews of Infectious Diseases 10, Suppl. 1, S138-9.
15. Sorget, F., Mahr, G., Stephan, U., Koch, H. U. & Wiesemann, H. G. (1988). Effect of normal and fat-rich food on the absorption of pefloxacin in humans. Reviews of Infectious Diseases 10, Suppl. 7, S137-S138.
16. Hooper, W. D., Dickinson, R. G. & Eadie, M. J. (1990). Effect of food on absorption of lomefloxacin. Antimicrobial Agents and Chemotherapy 34, 1797-9.
17. Dudley, M. N., Marchbanks, C. R., Flor, S. C. & Beals, B. (1991). The effect of food or milk on the absorption kinetics of ofloxacin. European Journal of Clinical Pharmacology 41, 569-71.
18. Williams, E. J. (1949). Experimental designs balanced for the estimation of residual effects of treatments. Australian Journal of Scientific Research 2, 149-68.
19. Teng, R., Tensfeldt, T. G., Liston, T. E. & Foulds, G. (1996). Determination of trovafloxacin, a new oral quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. Journal of Chromatography, B 675, 53-9.
20. Yuk, J. H., Nightingale, C. H., Quintiliani, R. & Sweeney, K. R. (1991). Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy 35, 384-6.
21. Fitton, A. (1992). The quinolones: an overview of their pharmacology. Clinical Pharmacokinetics 22, Suppl. 1, 1-11.
22. Neu, H. C. (1992). Quinolone antimicrobial agents. Annual Review of Medicine 43, 465-86.
23. Chang, T., Black, A., Dunky, A., Wolf, R., Sedman, A., Latts, J. et al. (1988). Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 21, Suppl. B, 49-56.
24. Radandt, J. M., Marchbanks, C. R. & Dudley, M. N. (1992). Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clinical Infectious Diseases 14, 272-84.